AC Immune SA (ACIU)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.2400 |
| Open | 3.2400 |
| Bid | 3.2000 x 800 |
| Ask | 3.2900 x 800 |
| Day's Range | 3.1200 - 3.3000 |
| 52 Week Range | 2.0600 - 12.6100 |
| Volume | |
| Avg. Volume | 92,632 |
| Market Cap | 234.668M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0700 |
| Earnings Date | Apr 26, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.71 |
- GlobeNewswire
AC Immune Holds Annual General Meeting of Shareholders
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders. Shareholders re-elected Douglas Williams, Monika BĂĽtler, Alan Colowick, Tom Graney, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Sh
- Insider Monkey
10 Unknown Biotech Stocks That Can Explode in 2022
In this article, we discuss the 10 unknown biotech stocks that can explode in 2022. If you want to read about some more biotech stocks that can explode in 2022, go directly to 5 Unknown Biotech Stocks That Can Explode in 2022. As coronavirus cases recede across the world and countries open up their borders […]
- Zacks
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
